Biomarkers for prostate cancer detection

Amanda Beth Reed, Dipen J Parekh

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarkers are needed for detecting prostate cancer and for determining which cancers need to be treated. This review will discuss the development of new biomarkers for prostate cancer detection and disease prognostication, focusing on recent progress and particular topical issues related to the development and validation of these new markers.

Original languageEnglish
Pages (from-to)103-114
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Biomarkers
Early Detection of Cancer
Neoplasms

Keywords

  • Biomarkers
  • Cancer
  • Prostate
  • Prostate-specific antigen
  • PSA
  • Tumor markers

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Biomarkers for prostate cancer detection. / Reed, Amanda Beth; Parekh, Dipen J.

In: Expert Review of Anticancer Therapy, Vol. 10, No. 1, 01.01.2010, p. 103-114.

Research output: Contribution to journalArticle

Reed, Amanda Beth ; Parekh, Dipen J. / Biomarkers for prostate cancer detection. In: Expert Review of Anticancer Therapy. 2010 ; Vol. 10, No. 1. pp. 103-114.
@article{a7ffe199496f4824b9e6a79a9dd5a83d,
title = "Biomarkers for prostate cancer detection",
abstract = "Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarkers are needed for detecting prostate cancer and for determining which cancers need to be treated. This review will discuss the development of new biomarkers for prostate cancer detection and disease prognostication, focusing on recent progress and particular topical issues related to the development and validation of these new markers.",
keywords = "Biomarkers, Cancer, Prostate, Prostate-specific antigen, PSA, Tumor markers",
author = "Reed, {Amanda Beth} and Parekh, {Dipen J}",
year = "2010",
month = "1",
day = "1",
doi = "10.1586/ERA.09.168",
language = "English",
volume = "10",
pages = "103--114",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Biomarkers for prostate cancer detection

AU - Reed, Amanda Beth

AU - Parekh, Dipen J

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarkers are needed for detecting prostate cancer and for determining which cancers need to be treated. This review will discuss the development of new biomarkers for prostate cancer detection and disease prognostication, focusing on recent progress and particular topical issues related to the development and validation of these new markers.

AB - Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarkers are needed for detecting prostate cancer and for determining which cancers need to be treated. This review will discuss the development of new biomarkers for prostate cancer detection and disease prognostication, focusing on recent progress and particular topical issues related to the development and validation of these new markers.

KW - Biomarkers

KW - Cancer

KW - Prostate

KW - Prostate-specific antigen

KW - PSA

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=74749109815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749109815&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.168

DO - 10.1586/ERA.09.168

M3 - Article

VL - 10

SP - 103

EP - 114

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -